ECSP12011836A - Nuevo uso antitumoral de cabazitaxel - Google Patents

Nuevo uso antitumoral de cabazitaxel

Info

Publication number
ECSP12011836A
ECSP12011836A ECSP12011836A ECSP12011836A EC SP12011836 A ECSP12011836 A EC SP12011836A EC SP12011836 A ECSP12011836 A EC SP12011836A EC SP12011836 A ECSP12011836 A EC SP12011836A
Authority
EC
Ecuador
Prior art keywords
cabazitaxel
new antitumoral
antitumoral use
prostate cancer
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
Sunil Gupta
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011836(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of ECSP12011836A publication Critical patent/ECSP12011836A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)

Abstract

La invención se refiere a un compuesto de fórmula (I): que puede estar en forma de base o en forma de hidrato o un solvato, en combinación con prednisona o prednisolona, para su uso como medicamento en el tratamiento del cáncer de próstata, particularmente cáncer metastásico de próstata, especialmente para pacientes que no siguen un tratamiento basado en taxano.
ECSP12011836 2009-10-29 2012-04-27 Nuevo uso antitumoral de cabazitaxel ECSP12011836A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US25616009P 2009-10-29 2009-10-29
US29390310P 2010-01-11 2010-01-11
US35583410P 2010-06-17 2010-06-17
US35588810P 2010-06-17 2010-06-17
US36992910P 2010-08-02 2010-08-02
US38393310P 2010-09-17 2010-09-17
US38996910P 2010-10-05 2010-10-05

Publications (1)

Publication Number Publication Date
ECSP12011836A true ECSP12011836A (es) 2012-07-31

Family

ID=43567614

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011836 ECSP12011836A (es) 2009-10-29 2012-04-27 Nuevo uso antitumoral de cabazitaxel

Country Status (31)

Country Link
US (8) US8927592B2 (es)
EP (1) EP2493466B1 (es)
JP (2) JP5566466B2 (es)
KR (1) KR101712231B1 (es)
CN (1) CN102770131A (es)
AR (1) AR078824A1 (es)
AU (4) AU2010310986A1 (es)
BR (1) BR112012011457A2 (es)
CA (1) CA2779009A1 (es)
CR (1) CR20120204A (es)
DK (1) DK2493466T3 (es)
EA (1) EA024186B1 (es)
EC (1) ECSP12011836A (es)
ES (1) ES2862340T3 (es)
GT (1) GT201200123A (es)
IL (3) IL219443A0 (es)
MA (1) MA33767B1 (es)
MX (1) MX336339B (es)
MY (1) MY164086A (es)
NI (1) NI201200071A (es)
PE (1) PE20121429A1 (es)
PH (1) PH12012500848A1 (es)
PL (1) PL2493466T3 (es)
PT (1) PT2493466T (es)
SG (1) SG10201810928SA (es)
SV (1) SV2012004192A (es)
TN (1) TN2012000188A1 (es)
TW (2) TWI654975B (es)
UY (1) UY32987A (es)
WO (1) WO2011051894A1 (es)
ZA (1) ZA201203123B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
AU2010310986A1 (en) 2009-10-29 2012-06-14 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
CN103764637A (zh) * 2011-04-12 2014-04-30 普拉斯化学品有限公司 卡巴他赛的固态形式及其制备方法
CN102503913B (zh) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
EP2791122B1 (en) 2011-12-13 2019-01-23 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
US9403785B2 (en) * 2012-01-03 2016-08-02 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
EP2880021A4 (en) 2012-07-31 2015-06-17 Yung Shin Pharm Ind Co Ltd AMORPHIC CABACITAXEL
TW201827417A (zh) * 2013-03-04 2018-08-01 法商安萬特醫藥公司 卡巴他賽(cabazitaxel)及其治療轉移性前列腺癌之用途
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2016133387A1 (en) 2015-02-17 2016-08-25 Erasmus University Medical Center Rotterdam Use of cabazitaxel in the treatment of prostate cancer
EP3093014A1 (en) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
US20190224332A1 (en) 2016-09-07 2019-07-25 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
US10195214B2 (en) * 2017-03-01 2019-02-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
WO2018187786A1 (en) * 2017-04-07 2018-10-11 La Jolla Institute For Allergy And Immunology Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof
US20250017891A1 (en) * 2023-07-04 2025-01-16 Twi Pharmaceuticals, Inc. Pharmaceutical composition comprising cabazitaxel prodrug-cyclodextrin inclusion complex, and applications thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5005588A (en) 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2732340B1 (fr) 1995-03-27 1997-04-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
ZA94128B (en) 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2745814B1 (fr) 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
KR20010079665A (ko) 1998-08-20 2001-08-22 추후제출 탁소이드 유도체의 신규 용도
US6403634B1 (en) 1999-01-13 2002-06-11 Aventis Pharma S.A. Use of taxoid derivatives
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
ATE302685T1 (de) 2003-07-02 2005-09-15 Scheuten Glasgroep Bv Verfahren zur herstellung einer brandschutzverglasung
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
JP5139811B2 (ja) 2004-12-08 2013-02-06 アベンティス・ファーマスーティカルズ・インコーポレイテツド ドセタキセル耐性または感受性の測定方法
EP1700596A1 (en) 2005-03-09 2006-09-13 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2177630A1 (en) 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
BRPI1014854A2 (pt) 2009-03-30 2016-05-03 Cerulean Pharma Inc "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
EA201200486A1 (ru) 2009-09-15 2012-08-30 Серулин Фарма Инк. Лечение онкологических заболеваний
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
AU2010310986A1 (en) 2009-10-29 2012-06-14 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
US8686165B2 (en) 2009-11-04 2014-04-01 Emcure Pharmaceuticals Limited Process for preparation of taxane derivatives
BR112012012210B8 (pt) 2009-11-23 2021-05-25 Cerulean Pharma Inc conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
US20130130928A1 (en) 2010-04-08 2013-05-23 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2011130317A2 (en) 2010-04-13 2011-10-20 Amplyx Pharmaceuticals Inc. Therapeutic agents having reduced toxicity
JP5975983B2 (ja) 2010-04-16 2016-08-23 ベリカム ファーマシューティカルズ， インコーポレイテッド 固形腫瘍を処置するための方法
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Also Published As

Publication number Publication date
TN2012000188A1 (en) 2013-12-12
JP2013509394A (ja) 2013-03-14
TW201127374A (en) 2011-08-16
JP2014196323A (ja) 2014-10-16
AU2016200598A1 (en) 2016-02-25
US10716777B2 (en) 2020-07-21
US20150118182A1 (en) 2015-04-30
AU2010310986A1 (en) 2012-06-14
IL219443A0 (en) 2012-06-28
PE20121429A1 (es) 2012-11-06
US20190151278A1 (en) 2019-05-23
US20120301425A1 (en) 2012-11-29
WO2011051894A1 (en) 2011-05-05
SG10201810928SA (en) 2019-01-30
IL250254A0 (en) 2017-03-30
CA2779009A1 (en) 2011-05-05
CR20120204A (es) 2012-07-04
US12453712B2 (en) 2025-10-28
EA201270606A1 (ru) 2013-01-30
US20180125810A1 (en) 2018-05-10
NI201200071A (es) 2012-08-20
US8927592B2 (en) 2015-01-06
US20150104411A1 (en) 2015-04-16
GT201200123A (es) 2013-11-07
ZA201203123B (en) 2013-06-26
KR101712231B1 (ko) 2017-03-03
US10583110B2 (en) 2020-03-10
MX2012005030A (es) 2012-12-05
PH12012500848A1 (en) 2016-02-08
TW201611831A (en) 2016-04-01
UY32987A (es) 2011-05-31
PT2493466T (pt) 2021-03-29
ES2862340T3 (es) 2021-10-07
TWI654975B (zh) 2019-04-01
BR112012011457A2 (pt) 2016-05-03
MX336339B (es) 2016-01-14
JP5566466B2 (ja) 2014-08-06
EP2493466A1 (en) 2012-09-05
US20240139146A1 (en) 2024-05-02
EA024186B1 (ru) 2016-08-31
TWI533866B (zh) 2016-05-21
MA33767B1 (fr) 2012-11-01
US20210169843A1 (en) 2021-06-10
US20200155497A1 (en) 2020-05-21
AU2017232227A1 (en) 2017-10-12
EP2493466B1 (en) 2021-03-10
MY164086A (en) 2017-11-30
DK2493466T3 (da) 2021-04-26
AR078824A1 (es) 2011-12-07
CN102770131A (zh) 2012-11-07
KR20120093986A (ko) 2012-08-23
JP6182510B2 (ja) 2017-08-16
PL2493466T3 (pl) 2021-11-15
SV2012004192A (es) 2012-08-23
IL267583A (en) 2019-08-29
AU2017232227B2 (en) 2019-06-06
AU2019203514A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
MX336339B (es) Nuevo uso antitumoral de cabazitaxel.
PH12016502066A1 (en) Methods of treating bladder cancer
EA201171367A1 (ru) Винилиндазолильные соединения
DOP2012000063A (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
CL2008001047A1 (es) Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata.
CL2015000711A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
CO6341625A2 (es) Derivados de indol como agentes anticáncer
EP2465494A4 (en) INJECTABLE COMPOSITION CONTAINING HYDROXYCHLOROQUINE FOR LOCAL ADMINISTRATION USED FOR THE TREATMENT OF CANCER
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
CL2014001323A1 (es) Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
EA201200190A1 (ru) Фулвестрант в дозе 500 мг для лечения распространенного рака молочной железы
UY32975A (es) Derivados de aminopiridina
CR20150442A (es) Cabazitaxel y su uso para el tratamiento de los cánceres de próstata metastásicos
ECSP11011550A (es) Procedimientos de uso del factor liberador de corticotropina para eltratamiento de cáncer
CO6531492A2 (es) Nuevo uso antitumoral de cabazitaxel
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
DOP2012000118A (es) Nuevo uso antitumoral de cabazitaxel
PH12014501794A1 (en) New pediatric uses of cabazitaxel
TN2014000342A1 (en) New pediatric uses of cabazitaxel
AR087392A1 (es) Combinacion antitumoral que comprende ombrabulina y cisplatino, asociada a radioterapia
LV14615A (lv) Līdzeklis karbonila olbaltumvielu līmeņa pazemināšanai asins plazmā